Welcome!

News Feed Item

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab

Phase 1b/2 trial with Genentech will assess the safety and efficacy of combining these investigational therapies for the treatment of triple-negative breast cancer

WALTHAM, Mass., Aug. 26, 2015 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with Genentech's atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer. Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells.

"Clinical development collaborations with industry leaders are an essential element of our strategy to realize the full potential of entinostat and position Syndax at the forefront of next-generation immuno-oncology therapy," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. "This collaboration expands our emerging immuno-oncology program into an important new indication. We are looking forward to collaborating with Genentech to study atezolizumab and entinostat in a breast cancer population with few treatment options."

Syndax will be responsible for conducting the Phase 1b/2 clinical trial in triple-negative breast cancer and the agreement includes a provision where the parties may extend the collaboration to include a Phase 3 clinical trial as well as additional trials in new indications of mutual interest.

About Syndax Pharmaceuticals, Inc.
Syndax is a clinical-stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated in a Phase 1b/2 clinical trial for non-small cell lung cancer and melanoma and in a Phase 3 clinical trial for advanced breast cancer. For more information on Syndax please visit www.syndax.com.

Cautionary Note on Forward-Looking Statements from Syndax
This press release contains forward-looking statements. Forward-looking statements contained in this press release include, without limitation, statements regarding the potential to extend the collaboration into new indications and Syndax's expectations regarding the development of its immuno-oncology program. Words such as "may," "believe," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of unknown risks, assumptions, uncertainties and factors that are beyond Syndax's control. All forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, Syndax expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Contacts

Investor and Media Relations:
Karen L. Bergman
BCC Partners
(650) 575-1509
[email protected]

Jen LaVin
BCC Partners
(207) 360-0473
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syndax-enters-clinical-trial-collaboration-in-cancer-immunotherapy-combining-entinostat-and-atezolizumab-300133302.html

SOURCE Syndax Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Emil Sayegh is an early pioneer of cloud computing and is recognized as one of the industry's true veterans. A cloud visionary, he is credited with launching and leading the cloud computing and hosting businesses for HP, Rackspace, and Codero. Emil built the Rackspace cloud business while serving as the company's GM of the Cloud Computing Division. Earlier at Rackspace he served as VP of the Product Group and launched the company's private cloud and hosted exchange services. He later moved o...
Today, Kubernetes is the defacto standard if you want to run container workloads in a production environment. As we set out to build our next generation of products, and run them smoothly in the cloud, we needed to move to Kubernetes too! In the process of building tools like KubeXray and GoCenter we learned a whole bunch. Join this talk to learn how to get started with Kubernetes and how we got started at JFrog building our new tools. After the session you will know: How we got to Kuberne...
The Crypto community has run out of anarchists, libertarians and almost absorbed all the speculators it can handle, the next 100m users to join Crypto need a world class application to use. What will it be? Alex Mashinsky, a 7X founder & CEO of Celsius Network will discuss his view of the future of Crypto.
Docker and Kubernetes are key elements of modern cloud native deployment automations. After building your microservices, common practice is to create docker images and create YAML files to automate the deployment with Docker and Kubernetes. Writing these YAMLs, Dockerfile descriptors are really painful and error prone.Ballerina is a new cloud-native programing language which understands the architecture around it - the compiler is environment aware of microservices directly deployable into infra...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, will discuss how to use Kubernetes to setup a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace....
When Enterprises started adopting Hadoop-based Big Data environments over the last ten years, they were mainly on-premise deployments. Organizations would spin up and manage large Hadoop clusters, where they would funnel exabytes or petabytes of unstructured data.However, over the last few years the economics of maintaining this enormous infrastructure compared with the elastic scalability of viable cloud options has changed this equation. The growth of cloud storage, cloud-managed big data e...
10ZiG Technology is a leading provider of endpoints for a Virtual Desktop Infrastructure environment. Our fast and reliable hardware is VMware, Citrix and Microsoft ready and designed to handle all ranges of usage - from task-based to sophisticated CAD/CAM users. 10ZiG prides itself in being one of the only companies whose sole focus is in Thin Clients and Zero Clients for VDI. This focus allows us to provide a truly unique level of personal service and customization that is a rare find in th...
Blockchain has shifted from hype to reality across many industries including Financial Services, Supply Chain, Retail, Healthcare and Government. While traditional tech and crypto organizations are generally male dominated, women have embraced blockchain technology from its inception. This is no more evident than at companies where women occupy many of the blockchain roles and leadership positions. Join this panel to hear three women in blockchain share their experience and their POV on the futu...
The vast majority of organizations today are in the earliest stages of AI initiatives and this shift will be dramatic as more enterprises move forward in the AI journey. Although companies are at different stages of this journey, most agree that finding or developing analytic talent is a key concern and bottleneck for doing more. What if your business could take advantage of the most advanced ML/AI models without the huge upfront time and investment inherent in building an internal ML/AI data sc...
Your applications have evolved, your computing needs are changing, and your servers have become more and more dense. But your data center hasn't changed so you can't get the benefits of cheaper, better, smaller, faster... until now. Colovore is Silicon Valley's premier provider of high-density colocation solutions that are a perfect fit for companies operating modern, high-performance hardware. No other Bay Area colo provider can match our density, operating efficiency, and ease of scalability.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
Take advantage of autoscaling, and high availability for Kubernetes with no worry about infrastructure. Be the Rockstar and avoid all the hurdles of deploying Kubernetes. So Why not take Heat and automate the setup of your Kubernetes cluster? Why not give project owners a Heat Stack to deploy Kubernetes whenever they want to? Hoping to share how anyone can use Heat to deploy Kubernetes on OpenStack and customize to their liking. This is a tried and true method that I've used on my OpenSta...
Serverless Architecture is the new paradigm shift in cloud application development. It has potential to take the fundamental benefit of cloud platform leverage to another level. "Focus on your application code, not the infrastructure" All the leading cloud platform provide services to implement Serverless architecture : AWS Lambda, Azure Functions, Google Cloud Functions, IBM Openwhisk, Oracle Fn Project.
The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get tailored market studies; and more.
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...